Ex-Hospira CEO Trades Shares for $91 Million Cash in Pfizer DealBy and
Pfizer completed purchase of injectable drugmaker Sept. 3
Executive's options vested in $90-a-share acquisition
Ball, who had run Lake Forest, Illinois-based Hospira since 2011, had 1.41 million shares and options when Pfizer completed its purchase of the company at $90 a share today, according to a regulatory filing. He spent $36 million to exercise his options, then sold shares valued at $127.1 million, according to data compiled from the filing.
Pfizer agreed in February to buy Hospira, which makes intravenous drugs and devices to deliver them, for $17 billion to bolster its roster of generic medicine.
Neha Wadhwa, a spokeswoman for New York-based Pfizer, declined to comment beyond the filing.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Stocks Turn Lower, Dollar Rises After Fed Minutes: Markets Wrap
- Risky Crypto Bet Dents Dennis Gartman's Retirement Account
- Apple in Talks to Buy Cobalt Directly From Miners
- Brighter U.S. Growth Outlook Emboldens Fed on Rate-Hike Course
- The House That Dimon Built: JPMorgan Plans Soaring HQ in Midtown